Health Catalyst (NASDAQ:HCAT) Receives Equal Weight Rating from Stephens

Stephens reissued their equal weight rating on shares of Health Catalyst (NASDAQ:HCAT) in a report published on Thursday,Benzinga reports. They currently have a $7.00 price objective on the stock.

Other analysts also recently issued reports about the company. Citigroup reduced their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research note on Friday, January 10th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a research report on Wednesday, January 8th. Royal Bank of Canada cut their target price on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 15th. Wells Fargo & Company cut their target price on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. Finally, Canaccord Genuity Group cut their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.45.

Health Catalyst Stock Performance

HCAT opened at $4.67 on Thursday. The business has a fifty day simple moving average of $5.98 and a 200 day simple moving average of $7.24. The company has a market capitalization of $284.16 million, a PE ratio of -3.46 and a beta of 1.34. Health Catalyst has a 1 year low of $3.76 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Insider Transactions at Health Catalyst

In other news, insider Linda Llewelyn sold 6,441 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total transaction of $34,974.63. Following the completion of the transaction, the insider now owns 85,819 shares of the company’s stock, valued at approximately $465,997.17. The trade was a 6.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total value of $30,003.84. Following the completion of the transaction, the chief operating officer now directly owns 86,044 shares of the company’s stock, valued at approximately $495,613.44. The trade was a 5.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 87,610 shares of company stock valued at $664,043. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Harbor Capital Advisors Inc. increased its holdings in Health Catalyst by 21.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after purchasing an additional 2,064 shares in the last quarter. Group One Trading LLC increased its holdings in Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after purchasing an additional 2,260 shares in the last quarter. Creative Planning increased its holdings in Health Catalyst by 13.2% in the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after purchasing an additional 2,486 shares in the last quarter. Two Sigma Securities LLC increased its holdings in Health Catalyst by 19.5% in the 4th quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock worth $124,000 after purchasing an additional 2,862 shares in the last quarter. Finally, Legato Capital Management LLC increased its stake in shares of Health Catalyst by 3.7% in the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after buying an additional 3,171 shares during the period. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.